FOR A RESPONSIBLE AND INNOVATIVE RESEARCH
FC3R is the French reference center for all 3Rs-related matters. It aims to support responsible use of animals for scientific research and to promote alternative and innovative methods.
New section on the website! Find all FC3R reports and publications online.
Opal Short Note Challenge!
The Opal will be awarded to the next 10 short notes
Discover the new guidance document on assessing the severity of animal experiments.
Next webinar on September 17, 2026: Insects and the 3Rs
"Les utilisations d’animaux en degré de gravité sévère",
report by the FC3R advisory board.
📅 Save the date! The next French 3Rs Day is taking place online on 2 July 2026.
Ce colloque est organisé en collaboration avec le Réseau Régional de Recherche sur l’Humain Recomposé et Reconstruit en Santé (HR2S). Il a pour ambition de fédérer les communautés de chimistes, physiciens, biologistes, cliniciens et partenaires SHS autour de la thématique des organoïdes.
Gratuite et ouverte à toutes et à tous sur inscription obligatoire, cette rencontre scientifique a pour ambition de promouvoir le principe des 3R – Remplacer, Réduire, Raffiner – et de valoriser les avancées majeures réalisées en France dans le domaine des méthodes alternatives et du bien-être animal.
Over the two days, we invite you to explore what we have been developing in the Open Research Programme (ORP), learn how this work can be adapted to your own context, and join dedicated topical sessions hosted by people from the UKRN community.
22.05.26
This database facilitates the identification of non-animal technologies, accelerates biomedical research, and promotes the ethical principles of the 3Rs.
21.05.26
According to the recommendation of the CNRS COMETS, the GIS FC3R Short Notes are establishing themselves as a practical tool for highlighting negative, inconclusive or confirmatory results.
05.03.26
The FC3R has awarded its 2025 3Rs Research Prize to Clémence Deligne for her publication on the development of an organoid biobank for the study and treatment of paediatric brain cancers.
